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Abstract
Background: Peritonitis continues to be the most frequent cause of peritoneal dialysis (PD)
failure, with an important impact on patient mortality. Gram-positive cocci such as Staphylococcus
epidermidis, other coagulase-negative staphylococci (CoNS), and Staphylococcus aureus are the most
frequent etiological agents of PD-associated peritonitis worldwide. The objective of the present
study was to compare peritonitis caused by S. aureus and CoNS and to evaluate the factors
influencing outcome.
Methods: Records of 86 new episodes of staphylococcal peritonitis that occurred between 1996
and 2000 in the Dialysis unit of a single university hospital were studied (35 due to S. aureus, 24 to
S. epidermidis and 27 to other CoNS). The production of slime, lipase, lecithinase, nuclease
(DNAse), thermonuclease (TNAse), α- and β-hemolysin, enterotoxins (SEA, SEB, SEC, SED) and
toxic shock syndrome toxin-1 (TSST-1) was studied in S. aureus and CoNS. Antimicrobial
susceptibility was evaluated based on the minimal inhibitory concentration determined by the E-
test. Outcome predictors were evaluated by two logistic regression models.
Results: The oxacillin susceptibility rate was 85.7% for S. aureus, 41.6% for S. epidermidis, and 51.8%
for other CoNS (p = 0.001). Production of toxins and enzymes, except for enterotoxin A and α-
hemolysin, was associated with S. aureus episodes (p < 0.001), whereas slime production was
positive in 23.5% of CoNS and 8.6% of S. aureus strains (p = 0.0047). The first model did not include
enzymes and toxins due to their association with S. aureus. The odds of resolution were 9.5 times
higher for S. epidermidis than for S. aureus (p = 0.02) episodes, and were similar for S. epidermidis
and other CoNS (p = 0.8). The resolution odds were 68 times higher for non-slime producers (p
= 0.001) and were not influenced by oxacillin resistance among vancomycin-treated cases (p =
0.89). In the second model, the resolution rate was similar for S. aureus and S. epidermidis (p = 0.70),
and slime (p = 0.001) and α-hemolysin (p = 0.04) production were independent predictors of non-
resolution.
Conclusion: Bacterial species and virulence factors rather than antibiotic resistance influence the
outcome of staphylococcal peritonitis.
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Peritonitis continues to be the most frequent cause of
peritoneal dialysis (PD) failure [1], and has an important
impact on patient mortality [2]. Gram-positive cocci such
as Staphylococcus epidermidis, other coagulase-negative sta-
phylococci (CoNS), and Staphylococcus aureus are the most
frequent etiological agents of PD-associated peritonitis
worldwide [3].
Previous studies comparing the outcome of peritonitis
caused by S. aureus and CoNS have shown a lower resolu-
tion rate and a higher frequency of complications in the
former [4-8]. Perez-Fontan et al [2] observed a mortality
rate of 15.2% for S. aureus episodes and of only 0.5% for
CoNS episodes. These findings are in contrast to the sus-
ceptibility profile observed for CoNS. According to Kim et
al [9], the frequency of methicillin-resistance among
CoNS increased from 18.4% in 1992-1993 to 41.7% in
2000-2001. Similar results have been reported by other
investigators [10]. Previous data from our group showed
that oxacillin resistance does not influence the outcome of
staphylococcal peritonitis [8].
In addition to species and antibiotic resistance, other fac-
tors related to the causal agent may influence the progno-
sis of peritonitis. Recurrence of CoNS infections is
frequently observed and has been suggested to be associ-
ated with the presence of a biofilm in the peritoneal cath-
eter [11]. Biofilm formation is related to the production of
an extracellular mucoid polysaccharide, called slime,
which permits microorganisms to adhere to plastic sur-
faces [12]. Kristinsson et al [13] reported a higher recur-
rence rate of peritonitis for slime-positive strains
compared to slime-negative ones, whereas Alexander and
Rimland [14] did not observe a relationship between
slime production and peritonitis outcome. In our unit,
slime production was found to be an independent risk
factor for the non-resolution of CoNS peritonitis [15].
The production of enzymes and toxins is a well-known
fact in Staphylococcus species, particularly S. aureus. Pro-
teases, lipases, nucleases, and collagenases convert tissue
components into nutrients, facilitating bacterial growth
and invasion [16], while toxic shock syndrome toxin
(TSST-1) and enterotoxins have effects such as superanti-
genicity, pyrogenicity, toxicity and direct damage to
endothelial [6].
Although these products are potential virulence factors in
staphylococcal PD-associated peritonitis, their influence
on the clinical outcome of these infections is unknown.
The objective of the present study was to compare the
capacity of traditional clinical and bacteriologic and
selected virulence factors such as production of slime,
enzymes and toxins to predict the outcome of new perito-
nitis episodes caused by S. aureus, S. epidermidis and other
CoNS.
Methods
Data collection and definitions
The present study was approved by the institutional Ethics
Committee. All episodes of continuous ambulatory peri-
toneal dialysis (CAPD)-associated peritonitis caused by
staphylococcal species between January 1996 and Decem-
ber 2000 were reviewed. This period was chosen because
a single antibiotic protocol based on the 1996 Update of
the International Society for Peritoneal Dialysis [17] was
used. After this period, new guidelines were proposed [18]
and adopted in our unit. The diagnosis of peritonitis was
made when at least two of the following criteria were
present: (a) presence of a cloudy peritoneal effluent, (b)
abdominal pain, (c) dialysate white cell count higher than
100/μL, with at least 50% polymorphonuclear cells, and
(d) positive culture of peritoneal effluent [17].
Only cases considered to be new episodes, i.e., a patient's
first peritonitis or an episode diagnosed at least 28 days
after completion of the last peritonitis treatment, were
included in the study [17]. Thus, 86 of 122 diagnosed sta-
phylococcal peritonitis episodes were analyzed. Exclusion
criteria were staphylococcal peritonitis within 28 days
prior to presentation, presence of concomitant exit site or
tunnel infections, incomplete clinical data, concomitant
antibiotic use for other indications, and use of an empiri-
cal antibiotic protocol other than the combination of
cefazolin and amikacin.
Resolution was defined as the disappearance of signs and
symptoms within 96 h after the beginning of antibiotic
therapy and a negative peritoneal fluid culture at least 28
days after treatment completion [7]. Relapse was defined
as an episode with the same organism or a negative cul-
ture result that occurs within 28 days of completion of
antibiotic therapy for a prior episode [17]. Non-resolution
was the term used for cases presenting initial non-resolu-
tion, relapse, peritoneal catheter removal, or death.
The following information was recorded for each case: (1)
episode: date, clinical findings, treatment, outcome (reso-
lution, relapse, catheter removal, or death); (2) presence
of diabetes mellitus; (3) demographic data: age, gender,
and race (Caucasian, non-Caucasian), dialysis treatment
time; (4) exchange system (standard or double bag).
Clinical management
All episodes were treated according to the local protocol
adapted from the third report of the Ad Hoc Advisory
Committee on Peritonitis Management for staphylococcal
episodes [17]. Patients were treated within 24 h of the
onset of the first clinical signs or symptoms and antibioticPage 2 of 8
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(patients with urine volume >500 mL/24 h) and 250 mg/
L amikacin, ip, as loading dose, followed by 500 or 750
mg/L cefazolin and 2 mg/kg amikacin per day in the last
PD bag. Therapy was evaluated as soon as the culture
results were available. For oxacillin-susceptible cocci,
cefazolin was maintained, whereas for oxacillin-resistant
cocci cefazolin was replaced with 1 g/L vancomycin, ip,
administered at intervals of 5 (patients with urine volume
>500 mL/24 h) or 7 days. Amikacin was discontinued in
both cases. Vancomycin was also administered to patients
who presented no clinical improvement within the first
96 h of antibiotic treatment, although the microbiological
tests revealed oxacillin susceptibility. The duration of anti-
biotic therapy was 14 days for CoNS episodes and 21 days
for S. aureus episodes.
Microbiological tests
Microbiological samples were stored in a culture collec-
tion. The isolates obtained from clinical specimens were
seeded onto blood agar and gram-stained to confirm
purity and to determine morphology and specific color.
The isolates were then submitted to catalase and coagu-
lase tests. CoNS were identified using the simplified bio-
chemical test scheme proposed by Kloos and Schleifer
[19] and Kloos and Bannerman [20].
In vitro susceptibility was evaluated based on the minimal
inhibitory concentration determined by the E-test (AB
Biodisk, Solna, Sweden), a quantitative method that uses
a transparent strip of inert plastic containing drug concen-
trations ranging from 0.002 to 256 μg/mL. The propor-
tion of strains susceptible to each drug was defined based
on the 2005 CLSI breakpoints [21]. Strains presenting
intermediate values were considered to be resistant.
Determination of the production of pathogenic factors
Slime
Slime production was evaluated according to Christensen
et al [22]. Colonies of CoNS isolated on blood agar were
inoculated into tubes measuring 12.0 × 75.0 mm and con-
taining 2.0 mL trypticase soy broth (TSB) and incubated
for 48 h at 37°C. Next, 1.0 mL 0.4% trypan blue or tolui-
dine blue O solution was added to the tubes. After gentle
shaking to guarantee staining of the material adhered to
the inner surface of the tubes, the dye was discarded. A
positive result was defined as the presence of a layer of
stained material adhered to the inner wall of the tubes.
The presence of a colored ring only at the liquid-air sur-
face was classified as negative.
Alpha- and beta-hemolysin
Production of α- and β-hemolysin or cytolytic toxins was
determined on plates containing blood agar base supple-
mented with 5% rabbit blood and 5% sheep blood,
respectively. The plates were incubated for 24 h at 37°C.
The formation of hemolysis zones around the isolated
colonies indicated a positive result.
Lipase and lecithinase
Lipolytic activity was determined on plates containing
blood agar base enriched with 0.01% CaCl2:2H2O and
1% Tween 80. A positive result was defined as the forma-
tion of opacity around the colony after incubation for 18
h at 37°C, followed by incubation at room temperature
for 24 h [23]. The production of lecithinase was evaluated
using Baird-Parker medium. The formation of an opaque
halo around the colony indicated a positive result [24].
DNAse and TNAse
Nuclease (DNAse) and thermonuclease (TNAse) were
determined by the metachromatic toluidine blue O agar
diffusion-DNA technique according to Lachica et al [25].
For the detection of DNAse, supernatants were obtained
from CoNS cultures in BHI broth previously incubated for
24 h at 37°C and centrifuged at 8000 g for 10 min at 4°C.
The culture supernatant was first heated in a water bath
for 20 min and then placed in the wells for the detection
of TNAse. Nuclease (DNAse and TNAse) activity was
determined by measuring the diameter of pink halos
(mm) formed on the medium. Positive results were inter-
preted by comparison of the halos with those obtained for
a standard DNAse- and TNAse-positive S. aureus strain
(ATCC 25923). Culture supernatants obtained by the sac
culture method of Donnelly et al [26], as described below,
were also tested for DNAse and TNAse production.
Enterotoxins and toxic shock syndrome toxin-1
The sac culture method for toxin production [26] was
used to determine the toxigenic profile of the strains. Dial-
ysis sacs filled with 50 mL double-concentrated BHI broth
were placed in U-shaped Erlenmeyer flasks and auto-
claved for 15 min at 121°C. A loopful of organisms was
added to 18 mL sterile 0.2 M phosphate buffer in 0.9%
NaCl, pH 7.4. After incubation for 24 h at 37°C on a
shaker at 200 rpm, the cultures were centrifuged at 8000 g
for 10 min at 4°C and the supernatants obtained were
stored at -20°C until the time of use. The extracellular
products were detected by reverse passive latex agglutina-
tion (RPLA) according to Shingaki et al [27], using the
SET-RPLA-T900 and TST-RPLA-TD940 kits (Oxoid Diag-
nostic Reagents) for the detection of enterotoxins A (SEA),
B (SEB), C (SEC) and D (SED) and TSST-1, respectively.
Culture supernatants were first treated with 5% (v/v) nor-
mal rabbit serum or 5% purified rabbit IgG to block non-
specific reactions. Samples that presented nonspecific
reactions even after this treatment were filtered through a
Millipore membrane (8.0 μm) and, if necessary, diluted
1:10 with 0.02 M phosphate buffer in 0.9% NaCl, pH 7.4.
A positive reaction was classified as (+), (++) and (+++)Page 3 of 8
(page number not for citation purposes)
BMC Infectious Diseases 2009, 9:212 http://www.biomedcentral.com/1471-2334/9/212according to the agglutination pattern described by the
manufacturer of the kit. The formation of a rose button
was interpreted as a negative result.
Statistical analysis
Continuous variables were compared using the unpaired
t-test or nonparametric Mann-Whitney U-test. Binary var-
iables were compared by the chi-square or Fisher's exact
test. Multivariate analysis by logistic regression was used
to test for factors that independently predicted the out-
come of a peritonitis episode, with outcome being classi-
fied into two mutually exhausted and exclusive results
(resolution or non-resolution). A model was adopted that
would incorporate the effect of all factors-interest and
control - on the outcome of infection. All baseline demo-
graphic, clinical, and microbiological variables, including
age, gender, diabetic status, dialysis duration, exchange
system, use of vancomycin, Staphylococcus species, oxacil-
lin susceptibility and pathogenic factor production, were
included in the model. A p value less than 0.05 was con-
sidered to be significant.
Results
Eighty-six new CAPD-associated staphylococcal peritoni-
tis episodes occurred in 63 patients between 1996 and
2000. Forty-three of the patients were females, 39 were
Caucasians, and 28 had diabetes. The distribution of
patients according to age was as follows: birth to 20 years
(n = 4), 21 to 40 years (n = 12), 41 to 59 years (n = 22),
and 60 years or older (n = 22). Treatment time on CAPD
was less than one year in 28 patients and longer than one
year in 35. Forty-four patients used a double bag system
and 19 used a standard bag exchange system.
Microbiological investigation
Thirty-five episodes were caused by S. aureus and 51 by
CoNS. Among CoNS, S. epidermidis was the most frequent
species (24 cases), followed by S. haemolyticus (11 cases)
and other species (16 cases) (Table 1).
Oxacillin susceptibility was observed in 30 (85.7%) of the
35 episodes due to S. aureus, in 10 (41.7%) of the 24 epi-
sodes due to S. epidermidis, and in 12 (44.4%) of the 27
episodes due to other CoNS (p = 0.0002). Five cases of
intermediate susceptibility were detected among CoNS
and one among S. aureus strains.
Positive slime production was observed in three cases due
to S. aureus (8.6%) and in nine (17.6%) due to CoNS (p =
0.345), including S. epidermidis in four, S. haemolyticus in
two, S. warneri in two, and S. lugdunensis in one.
With respect to toxigenic profile, 25 (71.4%) of the 35 S.
aureus strains were toxin producers, whereas only seven
(13.7%) of the 51 CoNS strains produced some type of
toxin (p < 0.00001). The rate of enzyme production was
higher in S. aureus strains than in S. epidermidis or other
CoNS, except for α-hemolysin whose production was sim-
ilar in all strains. The rates of toxin and enzyme produc-
tion by S. aureus, S. epidermidis and other CoNS species are
shown in Table 2.
Clinical outcome
Overall, 57 (66.3%) episodes were resolved, 14 (16.3%)
relapsed, 12 (13.9%) required removal of the catheter,
and three (3.5%) progressed to death. Among the 35 S.
aureus cases, 17 (48.6%) were resolved, eight (22.8%)
relapsed, seven (20%) required catheter removal, and
three (8.6%) progressed to death. Regarding CoNS epi-
sodes, 40 (78.4%) were resolved, six (11.8%) relapsed,
and five (9.8%) required catheter removal. Among these
11 non-resolved episodes, seven were due to S. epider-
midis, two to S. haemolyticus, and two to other CoNS. There
were significantly more CoNS cases resolved than S.
aureus episodes (p < 0.001).
There were 52 episodes involving oxacillin-susceptible
strains, 32 (61.5%) of them were resolved, 10 (19.2%)
relapsed, and 10 (19.2%) required catheter removal.
Thirty-four infections were caused by oxacillin-resistant
strains, 20 (58.8%) of them were resolved, nine (26.5%)
relapsed, and five (14.7%) required catheter removal. The
resolution rate was similar for oxacillin-susceptible and -
resistant strains (p = 0.9713).
Vancomycin was used in 56 episodes, 18 caused by S.
aureus and 38 by CoNS. This antibiotic was prescribed
because of bacterial resistance in 28 cases, lack of
improvement in 20, and other undefined causes in eight.
The time between diagnosis and the first vancomycin dose
was 3.7 ± 1.7 days for S. aureus episodes and 3.9 ± 1.2 days
for CoNS episodes (p = 0.793).
Two regression models were constructed. In Model 1
slime production was the only pathogenic factor, whereas
Table 1: Causative agent of the 86 new episodes of peritonitis 
caused by S. aureus and coagulase-negative staphylococci.
Microorganism No. of strains (%)
S. aureus 35
CoNS 51 (100)
S. epidermidis 24 (47)
S. haemolyticus 11 (21.5)
S. warneri 5 (9.8)
S. hominis 5 (9.8)
S. xylosus 2 (3.9)
S. cohnii 2 (3.9)
S. simulans 1 (1.9)
S. lugdunensis 1 (1.9)
CoNS: coagulase-negative staphylococci.Page 4 of 8
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included. Only lecithinase, α-hemolysin and TNAse were
included since associations were observed between leci-
thinase and lipase, α-hemolysin and β-hemolysin, and
TNAse and DNAse (p = 0.001). All toxins were included,
except for toxin D which was not produced by any of the
strains. Since an interaction effect was observed between
S. aureus species and oxacillin susceptibility (p = 0.01), the
influence of oxacillin susceptibility was evaluated at each
vancomycin treatment co-variable level in both models.
In Model 1 (Table 3), controlling for co-variables, the
odds of resolution was not influenced by host factors such
as age, gender, diabetes, exchange system, or CAPD treat-
ment time. The odds of resolution were 9.5 times higher
for S. epidermidis than for S. aureus episodes (p = 0.0263),
whereas similar resolution odds were observed for S. epi-
dermidis and the other CoNS (p = 0.085). Among strains
isolated from infections treated with vancomycin, no sig-
nificant difference was observed between oxacillin-sus-
ceptible and -resistant strains (p = 0.89). In contrast,
among strains isolated from infections not treated with
vancomycin, there was a significant difference between
strains susceptible and resistant to oxacillin (p = 0.0113).
In this case, the chance of cure of infections caused by oxa-
cillin-susceptible strains was 137 times higher than that of
Table 2: Rates of toxin and enzyme production by S. aureus, S. epidermidis and other coagulase-negative staphylococci strains isolated 
from 86 new episodes of peritonitis.
S. aureus S. epidermidis Other CoNS p
Toxins
SEA 4 (11.4) 1 (4.1) - (-) 0.15
SEB 12 (34.3) - (-) 2 (7.4) 0.0006
SEC 8 (22.8) - (-) 6 (22.2) 0.04*
SED - (-) - (-) - (-) -
TSST-1 12 (34.3) 1 (4.1) - (-) 0.0008
Enzymes
α-Hemolysin 17 (48.6) 8 (33.3) 8 (29.8) 0.26
β-Hemolysin 29 (82.3) 6 (25) 7 (25.9) < 0.00001
Lipase 34 (97.1) 4 (16.7) 5 (18.5) < 0.00001
Lecithinase 34 (97.1) 2 (8.3) 6 (22.2) < 0.00001
DNAse 34 (97.1) - (-) 4 (14.8) < 0.00001
TNAse 34 (97.1) - (-) 4 (14.8) < 0.00001
CoNS: coagulase-negative staphylococci; SEA, SEB, SEC, and SED: enterotoxins A, B, C and D, respectively; TSST-1: toxic shock syndrome toxin; * 
S. aureus vs. S. epidermidis and other CoNS vs. S. epidermidis.
Table 3: Odds comparison of peritonitis resolution by logistic regression analysis (Model 1).
Factor Log (Odds) p Odds ratio
(95% CI)
Age (birth to 20 years/>60 years) -0.0510 0.96
Age (21 to 40 years/>60 years) 1.7097 0.09
Age (41 to 59 years/>60 years) 0.7511 0.84
Gender (male/female) 1.2523 0.19
Race (Caucasian/non-Caucasian) -0.0818 0.92
Diabetes mellitus (no/yes) -0.6709 0.12
System (standard/double bag) 1.2585 0.22
Treatment time on CAPD
<1 year 0.2074 0.89
>1 year 0.9547 0.21
Treatment with vancomycin
Oxacillin susceptible/oxacillin resistant -0.1070 0.89
No treatment with vancomycin
Oxacillin susceptible/oxacillin resistant 1.9440 0.01 137 (3.0; 6,202.4)
Etiological agent
S. epidermidis/S. aureus 2.2548 0.02 9.5 (1.3; 69.6)
Other CoNS/S. epidermidis -1.6113 0.08
Slime production (no/yes) 4.2139 0.001 68 (5.0; 914.8)
CoNS: coagulase-negative staphylococci; CI: 95% Confidence Interval for the true Odds Ratio.Page 5 of 8
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slime production, the chance of cure of infections caused
by non-producers was estimated to be up to 68 times
higher than that of infections caused by slime producers
(p = 0.0015).
As observed for the first model, in Model 2 (Table 4) res-
olution odds were not influenced by host factors. Among
strains isolated from infections treated with vancomycin,
no significant difference was observed between those sus-
ceptible and resistant to oxacillin (p = 0.1523), whereas
there was a significant difference among strains not
treated with vancomycin (p = 0.0039). With respect to
slime production, the chance of cure of infections caused
by non-producers was estimated to be 184 times higher
than that of infections caused by producers (p = 0.0012).
In contrast to Model 1, S. aureus did not differ from S. epi-
dermidis in terms of the probability of peritonitis resolu-
tion (p = 0.7014), whereas the chance of cure of infections
caused by other CoNS species was estimated to be 46
times higher than that of infections caused by S. epider-
midis (p = 0.0175). Alpha-hemolysin production was an
independent predictor of resolution odds, with episodes
caused by non-producers presenting an 8.2 times higher
chance of resolution than those caused by producers (p =
0.0423). No significant effects on the probability of peri-
tonitis resolution were observed for the remaining
enzymes and toxins.
Discussion
In the present study we investigated new episodes of sta-
phylococcal peritonitis in PD patients and compared epi-
sodes caused by S. aureus, S. epidermidis and other CoNS,
focusing on the role of virulence factors in peritonitis out-
come. CoNS were the most frequent etiological agent, in
agreement with other studies. In addition to S. epidermidis,
seven other CoNS species were identified, the most pre-
dominant being S. haemolyticus. This is an important find-
ing since studies regarding other CoNS are scarce in the
literature.
The resolution rate of episodes caused by S. aureus was
lower than that of infections caused by CoNS. Similar
findings have been reported in the prospective studies of
Bunke et al [5] and Peacock et al [6], and in the recent ret-
rospective study of Davenport [1]. Since the rate of oxacil-
lin resistance was higher among CoNS strains than among
S. aureus strains, a contribution of drug resistance is
unlikely. In fact, our results showed no difference in reso-
Table 4: Odds comparison of peritonitis resolution by logistic regression analysis (Model 2).
Factor Log (Odds) p Odds ratio
(95% CI)
Age (birth to 20 years/>60 years) 0.0602 0.97
Age (21 to 40 years/>60 years) 4.2565 0.06
Age (41 to 59 years/>60 years) 1.9474 0.09
Gender (male/female) 1.2461 0.37
Race (Caucasian/non-Caucasian) -1.3322 0.21
Diabetes mellitus (no/yes) -0.6711 0.47
System (standard/double bags) 2.3397 0.12
Treatment time on CAPD
<1 year 0.0531 0.98
>1 year -0.3045 0.77
Treatment with vancomycin
Oxacillin susceptible/oxacillin resistant 1.6316 0.15
No treatment with vancomycin
Oxacillin susceptible/oxacillin resistant 10.0189 0.004 23,906 (25.4; exp{16.9274})
Etiological agent
S. epidermidis S. aureus -1.6481 0.70
Other CoNS/S. epidermidis 3.8238 0.017 46 (2.0; 1,069.4)
Slime production (no/yes) 5.2149 0.001 184 (7.8; 4,354.2)
Enzyme production (no/yes)




Enterotoxin A 2.3914 0.26
Enterotoxin B 0.5669 0.13
Enterotoxin C 4.0501 0.06
TSST-1 1.3694 0.48Page 6 of 8
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tible and oxacillin-resistant strains.
All patients received an intermittent regimen of cefazolin
plus amikacin as initial treatment. Some investigators
[28,29] argue that the continuous addition of beta-
lactams to the PD fluid is more effective for the treatment
of CoNS infections by overcoming moderate bacterial
resistance. Since a higher resolution rate was observed for
CoNS episodes compared to S. aureus episodes and the
number of strains presenting moderate resistance to oxa-
cillin was low, it is unlikely that the antibiotic regimen has
influenced the results.
Regression analysis using the two models showed no
influence of age, race, gender, CAPD treatment time, dia-
betes, or exchange system on the progression of peritoni-
tis. Similar results have been reported by Krishnan et al
[7], except for the influence of race and dialysis treatment
time.
Slime production was independently associated with
non-resolution of peritonitis. This finding agrees with
data on CoNS infections previously published by our
group [15] and with the results of Kristinsson et al [13].
The latter authors proposed that slime production may
promote bacterial adherence to catheters, facilitating col-
onization and peritonitis relapse. Thus, slime production
might be a virulence factor and simultaneously worsens
the response to infection, protecting bacterial cells from
the host's natural defense mechanisms and from the
action of antibiotics.
In contrast to Model 1, no difference in the probability of
peritonitis resolution was observed between S. aureus and
S. epidermidis when Model 2 was used. This finding might
be explained by the fact that inclusion of enzymes and
toxins in the model permitted the control for the effect of
species factor on these bacterial products. In other words,
the species effect observed in the first model for S. aureus
episodes was not separated from the pathogenicity factors
included in the second model. In addition, whereas the
chance of cure of S. epidermidis episodes compared to
other CoNS infections tended to be lower in the first
model, the second model showed a significantly lower
probability of cure of S. epidermidis episodes, an inde-
pendent outcome not influenced by toxin or enzyme pro-
duction.
Among the virulence factors studied, only α-hemolysin
production was significantly and independently associ-
ated with a higher probability of non-resolution. Recent
data published by Haslinger-Löffler et al [30] suggest that
α-hemolysin plays a specific role in the pathogenesis of
peritonitis. Using cultured human peritoneal mesothelial
cells, these authors showed that the S. aureus subgroup
characterized as invasive and α-hemolysin producing
induced caspase-independent cell death. Unlike S. aureus,
no cytotoxic effects were triggered by any of the S. epider-
midis strains which were noninvasive and did not produce
α-hemolysin. These findings, together with our results,
suggest that this enzyme plays a pathogenic role in PD-
associated peritonitis. Since mesothelial cells participate
in the early host defense against infections [31], damage
caused by α-hemolysin may contribute to the poor course
of S. aureus peritonitis.
This study has some limitations, particularly the small
number of cases, which reduce its statistical power and
prevented the separate analysis of S. aureus and CoNS
peritonitis episodes. Further studies with bigger number
of cases are necessary to overcome this limitation and to
confirm the present results.
Conclusions
In conclusion, host factors, as well as dialysis treatment
time and exchange system, probably have little or no
influence on the response to PD-associated peritonitis
treatment. However, the prognosis of these infections is
strongly influenced by characteristics of the causative
agent such as species and virulence factors. Although these
factors may act in concert, our data suggest that slime and
α-hemolysin production independently contribute to
poor peritonitis outcome.
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